Tesamorelin

Summary

Tesamorelin (CHEMBL1237026) is an approved protein (ATC H01AC06) targeting GHRHR; indicated across 5 conditions including chronic obstructive pulmonary disease and type 2 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H01AC06
• Targets: 1 (GHRHR)
• Indications: 5 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1237026
Name	Tesamorelin
Type	Protein
Max phase	4
ATC	H01AC06

Also known as: Egrifta, Tesamorelin, Tesamorelina, Tesamoreline, TH-9507, TH9507, TESAMORELIN

Parent form; salt/anhydrous children: CHEMBL2111290

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GHRHR	GHRH receptor	Agonist		0.2%	Q02643

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GHRHR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
G alpha (s) signalling events	1	GHRHR
Glucagon-type ligand receptors	1	GHRHR

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
lactation	1
positive regulation of cell population proliferation	1
determination of adult lifespan	1
growth hormone secretion	1
response to insulin	1
cellular response to insulin stimulus	1
regulation of intracellular steroid hormone receptor signaling pathway	1
positive regulation of multicellular organism growth	1
hormone metabolic process	1
positive regulation of insulin-like growth factor receptor signaling pathway	1
response to estrogen	1
positive regulation of circadian sleep/wake cycle, non-REM sleep	1
cell maturation	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
HIV infectious disease	1	MONDO:0005109	EFO:0000764

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	8
Not specified	5
PHASE4	2
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01591902	PHASE4	TERMINATED	Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
NCT03226821	PHASE4	TERMINATED	Body Composition and Adipose Tissue in HIV
NCT00123253	PHASE3	COMPLETED	TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00608023	PHASE3	COMPLETED	TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
NCT03150511	PHASE2	RECRUITING	Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
NCT06554717	PHASE2	RECRUITING	Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
NCT07481734	PHASE2	RECRUITING	Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
NCT01264497	PHASE2	COMPLETED	Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
NCT01388920	PHASE2	TERMINATED	Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
NCT02572323	PHASE2	COMPLETED	Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
NCT02931474	PHASE2	WITHDRAWN	Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
NCT03375788	PHASE2	COMPLETED	Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
NCT02012556	PHASE1	COMPLETED	Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
NCT01263717	Not specified	COMPLETED	Effects of Growth Hormone Releasing Hormone in HIV
NCT01579695	Not specified	TERMINATED	Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
NCT01632592	Not specified	WITHDRAWN	Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
NCT01788462	Not specified	WITHDRAWN	Egrifta Replacement and Sleep Disordered Breathing
NCT02196831	Not specified	COMPLETED	Tesamorelin Effects on Liver Fat and Histology in HIV

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

Molecule	Source	Status	Shared targets
DOCETAXEL	ChEMBL	Phase 4 (approved)	GHRHR